A randomised wait-list controlled trial to evaluate Emotional Freedom Techniques for self-reported cancer-related cognitive impairment in cancer survivors (EMOTICON).

Cancer survivorship Cancer-related cognitive impairment Emotional freedom techniques Subjective cognitive complaints

Journal

EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 28 05 2021
revised: 21 07 2021
accepted: 22 07 2021
entrez: 1 9 2021
pubmed: 2 9 2021
medline: 2 9 2021
Statut: epublish

Résumé

Cancer-related cognitive impairment (CRCI) is a prevalent source of comprised quality of life in cancer survivors. This study evaluated the efficacy of Emotional Freedom Techniques (EFT) on self-reported CRCI (sr-CRCI). In this prospective multicentre randomised wait-list controlled study (ClinicalTrials.gov Identifier: NCT02771028), eligible cancer survivors had completed curative treatment, were 18 years or older and screened positive for sr-CRCI with ≥ 43 on the Cognitive Failures Questionnaire (CFQ). Participants were randomised to the immediate treatment group (ITG) or wait-list control (WLC) group, based on age (< or ≥ 65 years), gender, treatment (chemotherapy or not), and centre. The ITG started to apply EFT after inclusion and performed this for 16 weeks. The WLC group could only start the application of EFT after 8 weeks of waiting. Evaluations took place at baseline (T0), 8 weeks (T1) and 16 weeks (T2). The primary outcome was the proportion of patients with sr-CRCI according to the CFQ score. Between October 2016 and March 2020, 121 patients were recruited with CFQ ≥ 43 indicating sr-CRCI. At T1, the number of patients scoring positive on the CFQ was significantly reduced in the ITG compared to the WLC group (40.8% vs. 87.3% respectively; This study provides evidence for the application of EFT for sr-CRCI in cancer survivors and suggests that EFT may be useful for other symptoms in cancer survivors.

Sections du résumé

BACKGROUND BACKGROUND
Cancer-related cognitive impairment (CRCI) is a prevalent source of comprised quality of life in cancer survivors. This study evaluated the efficacy of Emotional Freedom Techniques (EFT) on self-reported CRCI (sr-CRCI).
METHODS METHODS
In this prospective multicentre randomised wait-list controlled study (ClinicalTrials.gov Identifier: NCT02771028), eligible cancer survivors had completed curative treatment, were 18 years or older and screened positive for sr-CRCI with ≥ 43 on the Cognitive Failures Questionnaire (CFQ). Participants were randomised to the immediate treatment group (ITG) or wait-list control (WLC) group, based on age (< or ≥ 65 years), gender, treatment (chemotherapy or not), and centre. The ITG started to apply EFT after inclusion and performed this for 16 weeks. The WLC group could only start the application of EFT after 8 weeks of waiting. Evaluations took place at baseline (T0), 8 weeks (T1) and 16 weeks (T2). The primary outcome was the proportion of patients with sr-CRCI according to the CFQ score.
FINDINGS RESULTS
Between October 2016 and March 2020, 121 patients were recruited with CFQ ≥ 43 indicating sr-CRCI. At T1, the number of patients scoring positive on the CFQ was significantly reduced in the ITG compared to the WLC group (40.8% vs. 87.3% respectively;
INTERPRETATION CONCLUSIONS
This study provides evidence for the application of EFT for sr-CRCI in cancer survivors and suggests that EFT may be useful for other symptoms in cancer survivors.

Identifiants

pubmed: 34466793
doi: 10.1016/j.eclinm.2021.101081
pii: S2589-5370(21)00361-8
pmc: PMC8385168
doi:

Banques de données

ClinicalTrials.gov
['NCT02771028']

Types de publication

Journal Article

Langues

eng

Pagination

101081

Informations de copyright

© 2021 The Author(s).

Déclaration de conflit d'intérêts

All authors have no conflicts of interest to declare, except for co-author dr. Christel Fontaine who received financial support for attending online ESMO 2020, ICOS 2020, SABCS 2020, EBCC 2021, ASCO 2021, MASCC 2021, ECHNO 2021.

Références

J Behav Ther Exp Psychiatry. 2015 Sep;48:140-8
pubmed: 25863484
J Clin Oncol. 2020 Jun 10;38(17):1871-1874
pubmed: 32142394
J Clin Oncol. 2012 Oct 20;30(30):3675-86
pubmed: 23008308
Psychooncology. 2013 Aug;22(8):1783-9
pubmed: 23109296
J Psychosoc Oncol. 2019 Jul-Aug;37(4):427-440
pubmed: 30798774
J Clin Oncol. 2017 Jan 10;35(2):217-225
pubmed: 28056205
J Clin Oncol. 2018 Sep 21;:JCO2018786624
pubmed: 30240328
Depress Res Treat. 2012;2012:257172
pubmed: 22848802
Psychooncology. 2015 Nov;24(11):1360-7
pubmed: 25759235
Psychooncology. 2015 Apr;24(4):402-7
pubmed: 25044780
J Cancer Surviv. 2018 Aug;12(4):537-559
pubmed: 29728959
J Clin Oncol. 2015 Dec 1;33(34):4085-92
pubmed: 26527785
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2013;20(5):532-52
pubmed: 23237718
J Clin Oncol. 1998 Jan;16(1):139-44
pubmed: 9440735
Trends Neurosci. 2018 Aug;41(8):493-496
pubmed: 29907436
J Nerv Ment Dis. 2012 Oct;200(10):891-6
pubmed: 22986277
Cancer Invest. 2007 Sep;25(6):373-7
pubmed: 17882646
J Nerv Ment Dis. 2014 Oct;202(10):699-709
pubmed: 25265265
Am J Health Promot. 2018 Jan;32(1):112-122
pubmed: 27520015
Ann Oncol. 2019 Dec 1;30(12):1925-1940
pubmed: 31617564
J Nerv Ment Dis. 2016 May;204(5):388-95
pubmed: 26894319
Psychooncology. 2015 Jun;24(6):676-82
pubmed: 25345397
Br J Clin Psychol. 1982 Feb;21(1):1-16
pubmed: 7126941
Psychooncology. 2017 May;26(5):632-639
pubmed: 27338029
Psychotherapy (Chic). 2010 Sep;47(3):385-402
pubmed: 22402094
J Evid Based Integr Med. 2019 Jan-Dec;24:2515690X18823691
pubmed: 30777453
J Natl Cancer Inst. 2020 Feb 1;112(2):123-127
pubmed: 31504664
Eur Urol Focus. 2016 Dec 15;2(6):642-649
pubmed: 28723499
Explore (NY). 2016 Nov - Dec;12(6):416-426
pubmed: 27843054
Brain Imaging Behav. 2019 Feb;13(1):15-26
pubmed: 28466438
J Nerv Ment Dis. 2018 Oct;206(10):783-793
pubmed: 30273275
J Geriatr Oncol. 2016 Jul;7(4):270-80
pubmed: 27197918
J Cancer Surviv. 2018 Apr;12(2):178-185
pubmed: 29080061
J Clin Oncol. 2017 Feb 10;35(5):506-514
pubmed: 28029304
J Psychosoc Oncol. 2017 Nov-Dec;35(6):741-757
pubmed: 28816636
J Natl Cancer Inst. 2013 Jun 5;105(11):791-801
pubmed: 23606729
Med Acupunct. 2017 Aug 1;29(4):194-205
pubmed: 28874920
Psychooncology. 2012 May;21(5):479-87
pubmed: 21351188
Integr Med (Encinitas). 2016 Apr;15(2):27-34
pubmed: 27330487
J Clin Oncol. 2019 Apr 1;37(10):834-849
pubmed: 30702028
Explore (NY). 2017 Jan - Feb;13(1):16-25
pubmed: 27889444
Front Oncol. 2015 Mar 25;5:72
pubmed: 25859431
J Nerv Ment Dis. 2013 Feb;201(2):153-60
pubmed: 23364126
Oncology (Williston Park). 2014 Sep;28(9):797-804
pubmed: 25224480

Auteurs

Laura Tack (L)

Department of Medical Oncology, Kortrijk Cancer Centre, AZ Groeninge, Pres. Kennedylaan 4, Kortrijk B-8500, Belgium.
Department of Radiation Oncology and Experimental Cancer Research, Ghent University, Ghent, Belgium.

Tessa Lefebvre (T)

Department of Medical Oncology, Kortrijk Cancer Centre, AZ Groeninge, Pres. Kennedylaan 4, Kortrijk B-8500, Belgium.

Michelle Lycke (M)

Department of Medical Oncology, Kortrijk Cancer Centre, AZ Groeninge, Pres. Kennedylaan 4, Kortrijk B-8500, Belgium.

Chistine Langenaeken (C)

Department of Medical Oncology, AZ Klina, Brasschaat, Belgium.

Christel Fontaine (C)

Department of Medical Oncology, UZ Brussel, Brussels, Belgium.

Marleen Borms (M)

Department of Medical Oncology, Kortrijk Cancer Centre, AZ Groeninge, Pres. Kennedylaan 4, Kortrijk B-8500, Belgium.

Marianne Hanssens (M)

Department of Medical Oncology, Kortrijk Cancer Centre, AZ Groeninge, Pres. Kennedylaan 4, Kortrijk B-8500, Belgium.
Department of Medical Oncology, Sint-Jozefskliniek Izegem, Izegem, Belgium.

Christel Knops (C)

Department of Medical Oncology, AZ Klina, Brasschaat, Belgium.

Kathleen Meryck (K)

Independent EFT Practitioner, London, United Kingdom.

Tom Boterberg (T)

Department of Radiation Oncology and Experimental Cancer Research, Ghent University, Ghent, Belgium.

Hans Pottel (H)

Department of Public Health and Primary Care @ Kulak, Catholic University Leuven Kulak, Kortrijk, Belgium.

Patricia Schofield (P)

Sheffield Hallam University, Sheffield, United Kingdom.

Philip R Debruyne (PR)

Department of Medical Oncology, Kortrijk Cancer Centre, AZ Groeninge, Pres. Kennedylaan 4, Kortrijk B-8500, Belgium.
Medical Technology Research Centre, School of Life Sciences, Faculty of Science and Engineering, Anglia Ruskin University, Cambridge, United Kingdom.

Classifications MeSH